A detailed history of New York State Common Retirement Fund transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 12,132 shares of DAWN stock, worth $161,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,132
Previous 20,032 39.44%
Holding current value
$161,476
Previous $276,000 38.77%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$12.72 - $16.03 $100,488 - $126,637
-7,900 Reduced 39.44%
12,132 $169,000
Q2 2024

Jul 31, 2024

SELL
$12.03 - $17.69 $555,737 - $817,207
-46,196 Reduced 69.75%
20,032 $276,000
Q1 2024

May 07, 2024

SELL
$13.56 - $17.46 $163,682 - $210,759
-12,071 Reduced 15.42%
66,228 $1.09 Million
Q4 2023

Feb 01, 2024

BUY
$9.68 - $15.37 $128,685 - $204,328
13,294 Added 20.45%
78,299 $1.14 Million
Q3 2023

Nov 07, 2023

SELL
$11.22 - $14.86 $90,444 - $119,786
-8,061 Reduced 11.03%
65,005 $798,000
Q2 2023

Aug 07, 2023

BUY
$11.74 - $14.47 $221,075 - $272,484
18,831 Added 34.72%
73,066 $872,000
Q1 2023

May 02, 2023

BUY
$12.75 - $23.41 $30,880 - $56,699
2,422 Added 4.67%
54,235 $725,000
Q4 2022

Jan 30, 2023

BUY
$18.77 - $22.0 $431 - $506
23 Added 0.04%
51,813 $1.12 Million
Q3 2022

Nov 08, 2022

BUY
$16.44 - $26.57 $531,373 - $858,795
32,322 Added 166.03%
51,790 $1.04 Million
Q2 2022

Aug 04, 2022

BUY
$5.72 - $17.9 $331 - $1,038
58 Added 0.3%
19,468 $348,000
Q1 2022

May 05, 2022

BUY
$9.12 - $17.47 $103,128 - $197,550
11,308 Added 139.57%
19,410 $193,000
Q4 2021

Feb 02, 2022

BUY
$15.65 - $26.33 $126,796 - $213,325
8,102 New
8,102 $137,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $978M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.